After the first full day of sessions at the 2016 Conference on Retroviruses and
Opportunistic Infections (CROI) in Boston yesterday, February 23, we caught up with Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID), to get his take on some of the key highlights of the day.
In this brief video he highlights two important presentations about improvements in antiretroviral therapy (ART) and the next generation of both HIV treatment and HIV prevention. These included discussions about therapies that maintain their effectiveness over long periods of time that could be delivered as a monthly injection instead of as a daily pill. Dr. Dieffenbach highlighted, specifically, a plenary session by Dr. Joe Eron of UNC Chapel Hill titled “Antiretroviral Therapy: Where Are We Now? Where Are We Going?” and another session by Dr. Ian McGowan of the University of Pittsburgh School of Medicine titled “The Promise and Challenges of Sustained Delivery of PrEP” .
The annual CROI conference has assembled nearly 4,000 basic, translational, and clinical researchers from 96 countries to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases.
Tomorrow Dr. Dieffenbach will return to share brief highlights of the science presented on Wednesday, February 24.